{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:15:29Z","timestamp":1791166529137,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.diabres.2008.01.009","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T23:37:19Z","timestamp":1204846639000},"page":"344-351","source":"Crossref","is-referenced-by-count":67,"title":["Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials"],"prefix":"10.1016","volume":"80","author":[{"given":"Konstantinos Z.","family":"Vardakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Horianopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2008.01.009_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0002-9610(98)00181-0","article-title":"The burden of diabetic foot ulcers","volume":"176","author":"Reiber","year":"1998","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.diabres.2008.01.009_bib2","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(05)67699-4","article-title":"Treatment for diabetic foot ulcers","volume":"366","author":"Cavanagh","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2008.01.009_bib3","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2337\/diacare.28.8.1869","article-title":"Foot ulcer risk is lower in South-Asian and African-Caribbean compared with European diabetic patients in the U.K.: the North-West diabetes foot care study","volume":"28","author":"Abbott","year":"2005","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabres.2008.01.009_bib4","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1111\/j.1464-5491.2004.1424-8.x","article-title":"MRSA and osteomyelitis of the foot in diabetes","volume":"21","author":"Game","year":"2004","journal-title":"Diab. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib5","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1464-5491.2004.01237.x","article-title":"Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact","volume":"21","author":"Hartemann-Heurtier","year":"2004","journal-title":"Diab. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib6","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1002\/dmrr.441","article-title":"Diagnosing and treating diabetic foot infections","volume":"20","author":"Lipsky","year":"2004","journal-title":"Diab. Metab. Res. Rev."},{"key":"10.1016\/j.diabres.2008.01.009_bib7","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.amjsurg.2003.10.008","article-title":"An evidence-based approach to diabetic foot infections","volume":"186","author":"Frykberg","year":"2003","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.diabres.2008.01.009_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1086\/424846","article-title":"Diagnosis and treatment of diabetic foot infections","volume":"39","author":"Lipsky","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijantimicag.2005.07.017","article-title":"Sequential intravenous\/oral moxifloxacin versus intravenous piperacillin\u2013tazobactam followed by oral amoxicillin\u2013clavulanate for the treatment of complicated skin and skin structure infection","volume":"26","author":"Giordano","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diabres.2008.01.009_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/sur.2005.6.27","article-title":"An open-label, randomized study comparing efficacy and safety of intravenous piperacillin\/tazobactam and ampicillin\/sulbactam for infected diabetic foot ulcers","volume":"6","author":"Harkless","year":"2005","journal-title":"Surg. Infect. (Larchmt)"},{"key":"10.1016\/j.diabres.2008.01.009_bib11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(05)67694-5","article-title":"Ertapenem versus piperacillin\/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trial","volume":"366","author":"Lipsky","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2008.01.009_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkh531","article-title":"Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections","volume":"55","author":"Lipsky","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diabres.2008.01.009_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.amjopharm.2004.09.006","article-title":"Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin\/clavulanate every 6h as empiric treatment for diabetic lower-extremity infections in older males","volume":"2","author":"Clay","year":"2004","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.diabres.2008.01.009_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/380449","article-title":"Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin\u2013sulbactam\/amoxicillin\u2013clavulanate","volume":"38","author":"Lipsky","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/341026","article-title":"Once-daily, high-dose levofloxacin versus ticarcillin\u2013clavulanate alone or followed by amoxicillin\u2013clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial","volume":"35","author":"Graham","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1086\/340348","article-title":"Ertapenem once daily versus piperacillin\u2013tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study","volume":"34","author":"Graham","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/AAC.45.2.525-531.2001","article-title":"Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections","volume":"45","author":"Siami","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diabres.2008.01.009_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/153857449703100403","article-title":"Prospective, randomized comparison of ampicillin\/sulbactam and cefoxitin for diabetic foot infections","volume":"31","author":"Erstad","year":"1997","journal-title":"Vasc. Surg."},{"key":"10.1016\/j.diabres.2008.01.009_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/clind\/24.4.643","article-title":"Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens","volume":"24","author":"Lipsky","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-8579(96)00305-6","article-title":"Treatment of diabetic foot infection: an open randomized comparison of imipenem\/cilastatin and piperacillin\/clindamycin combination therapy","volume":"7","author":"Bouter","year":"1996","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diabres.2008.01.009_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/clinids\/18.5.683","article-title":"Use of ampicillin\/sulbactam versus imipenem\/cilastatin in the treatment of limb-threatening foot infections in diabetic patients","volume":"18","author":"Grayson","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib22","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.37.8.1580","article-title":"Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin\/Tazobactam Skin and Skin Structure Study Group","volume":"37","author":"Tan","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diabres.2008.01.009_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/archinte.150.4.790","article-title":"Outpatient management of uncomplicated lower-extremity infections in diabetic patients","volume":"150","author":"Lipsky","year":"1990","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0002-9343(89)90476-2","article-title":"Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both","volume":"86","author":"Peterson","year":"1989","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib25","first-page":"S36","article-title":"Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime","volume":"10","author":"Hughes","year":"1987","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diabres.2008.01.009_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/0002-9343(83)90103-1","article-title":"Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections)","volume":"75","author":"File","year":"1983","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1464-5491.2006.01785.x","article-title":"Systematic review of antimicrobial treatments for diabetic foot ulcers","volume":"23","author":"Nelson","year":"2006","journal-title":"Diab. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","article-title":"Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"189","author":"Sharpe","year":"2005","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.diabres.2008.01.009_bib29","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diabres.2008.01.009_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jac\/dkh048","article-title":"Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study","volume":"53","author":"Cepeda","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diabres.2008.01.009_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diabres.2008.01.009_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diabres.2008.01.009_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.inf.0000059403.21440.2c","article-title":"Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children","volume":"22","author":"Wible","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diabres.2008.01.009_bib34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib35","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.44.12.3408-3413.2000","article-title":"Randomized comparison of linezolid (PNU-100766) versus oxacillin\u2013dicloxacillin for treatment of complicated skin and soft tissue infections","volume":"44","author":"Stevens","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diabres.2008.01.009_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/381029","article-title":"Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases consultants","volume":"38","author":"Perencevich","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1464-5491.1999.00132.x","article-title":"Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic","volume":"16","author":"Tentolouris","year":"1999","journal-title":"Diab. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1469-0691.2005.01279.x","article-title":"Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers","volume":"12","author":"Tentolouris","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diabres.2008.01.009_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2337\/diacare.12.6.373","article-title":"Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer","volume":"12","author":"Apelqvist","year":"1989","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabres.2008.01.009_bib40","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/archsurg.1990.01410240045010","article-title":"The influence of renal function on diabetic foot ulceration","volume":"125","author":"Griffiths","year":"1990","journal-title":"Arch. Surg."},{"key":"10.1016\/j.diabres.2008.01.009_bib41","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/dc05-2425","article-title":"Risk factors for foot infections in individuals with diabetes","volume":"29","author":"Lavery","year":"2006","journal-title":"Diab. Care"},{"key":"10.1016\/j.diabres.2008.01.009_bib42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1525-1497.1997.07108.x","article-title":"Prognostic value of the clinical examination of the diabetic foot ulcer","volume":"12","author":"Edelman","year":"1997","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib43","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1464-5491.1990.tb01454.x","article-title":"The importance of peripheral pulses, peripheral oedema and local pain for the outcome of diabetic foot ulcers","volume":"7","author":"Apelqvist","year":"1990","journal-title":"Diab. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/1056-8727(92)90032-G","article-title":"Medical risk factors in diabetic patients with foot ulcers and severe peripheral vascular disease and their influence on outcome","volume":"6","author":"Apelqvist","year":"1992","journal-title":"J. Diab. Complicat."},{"key":"10.1016\/j.diabres.2008.01.009_bib45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archinte.159.8.851","article-title":"Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up","volume":"159","author":"Pittet","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diabres.2008.01.009_bib46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/s-0029-1212006","article-title":"Amputation rate in 147 Turkish patients with diabetic foot: the Hacettepe University Hospital experience","volume":"106","author":"Gurlek","year":"1998","journal-title":"Exp. Clin. Endocrinol. Diab."},{"key":"10.1016\/j.diabres.2008.01.009_bib47","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/107110079701801107","article-title":"Clinical characteristics and outcome in 223 diabetic patients with deep foot infections","volume":"18","author":"Eneroth","year":"1997","journal-title":"Foot Ankle Int."},{"key":"10.1016\/j.diabres.2008.01.009_bib48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5435\/00124635-199507000-00004","article-title":"The diabetic foot","volume":"3","author":"Laughlin","year":"1995","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"10.1016\/j.diabres.2008.01.009_bib49","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/511036","article-title":"Validation of the infectious diseases society of America's diabetic foot infection classification system","volume":"44","author":"Lavery","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diabres.2008.01.009_bib50","first-page":"569","article-title":"Diabetic foot\u2014uncontrollable infections despite successful revascularization","volume":"114","author":"Wack","year":"1997","journal-title":"Langenbecks Arch. Chir. Suppl. Kongressbd."},{"key":"10.1016\/j.diabres.2008.01.009_bib51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2337\/diacare.28.2.454","article-title":"Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis","volume":"28","author":"Cruciani","year":"2005","journal-title":"Diab. Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822708000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822708000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T07:20:37Z","timestamp":1546240837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822708000193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0168822708000193"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2008.01.009","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}